Regenerative Medical Technology Group Inc. focuses on the regenerative medicine industry after acquiring Global Stem Cell Group in August 2021. The company believes stem cell therapy offers an effective clinical alternative to traditional surgery and conventional pharmaceuticals that often provide only palliative care. It works with doctors and their staff to supply products, solutions, equipment, and training that support the application of stem cell therapies. In addition to supporting physicians, the company directly performs patient procedures at its clinic in Cancun Mexico and at a planned joint venture clinic in the Jumeirah area of Dubai United Arab Emirates. Regenerative Medical Technology Group Inc. combines insights from clinical research with the manufacturing and commercialization of viable cell therapy and immune support related products. Its strategy aims to create immediate revenue streams through patient treatments, educational programs, product sales, distribution, and the ongoing use of its proprietary kits and solutions. Global Stem Cell Group is recognized as a leader in stem cell and regenerative medicine fields, covering research, patient applications, and physician training through a global network of companies. Its mission is to enable physicians to make the benefits of stem cell medicine a reality for patients worldwide. The International Society for Stem Cell Application ISCCA serves as a trademarked professional association that links medical professionals across countries to share best practices and advance the company’s mission.
Revenue is generated from multiple interconnected streams. The company receives payment for direct patient treatments administered at its clinics. It earns fees from training seminars, certification programs, and educational events delivered through the International Society for Stem Cell Application. Sales of stem cell kits, equipment, and related products contribute to income, as does the resale of these items to third party distributors. Recurring revenue arises from the continued application of the company’s proprietary processes by healthcare providers who use the supplied kits and solutions. Additionally, the company’s product development division Celgenic sells mesenchymal stem cell based preparations, exosome isolates, and peptide based formulations to both its clinic network and external customers. The combination of treatment services, education, product sales, and distribution creates a diversified revenue base that reduces reliance on any single source.
Regenerative Medical Technology Group Inc. has established a notable position within the regenerative medicine sector by integrating education, manufacturing, and clinical service delivery under 1 corporate structure. This vertical integration contrasts with many competitors that concentrate on either product development, physician training, or clinic operations alone. The company’s educational arm the International Society for Stem Cell Application has trained medical professionals in more than 20 countries across Africa, Asia, Europe, North America, and South America, creating a widespread network of practitioners familiar with its protocols. Its manufacturing facility in Cancun Mexico has received full accreditation from Cofepris the Mexican equivalent of the FDA, allowing production of mesenchymal stem cells, exosomes, and peptide based products under strict quality controls. The presence of owned clinics in Cancun and the planned facility in Dubai further strengthens control over treatment delivery and ensures consistent application of its therapeutic approaches. These combined capabilities give Regenerative Medical Technology Group Inc. a competitive edge in providing high quality, standardized regenerative medicine solutions to a global clientele.
The company serves a diverse customer base that includes physicians and other medical professionals seeking training and certification in stem cell based therapies. It also supplies clinics, hospitals, and private practices with regenerative medicine products such as mesenchymal stem cell preparations, exosomes, and peptide based formulations. Patients who undergo treatment at company operated facilities represent another important segment of the clientele. While the filing does not disclose specific customer names, the company reports that its educational programs have reached professionals in over 20 countries and that its clinic network serves individuals in Mexico, the Caribbean, Europe, and the Middle East. This broad base of doctors, healthcare institutions, and patients supports the company’s goal of making stem cell medicine accessible worldwide.